Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06582875 · ClinicalTrials.gov registry record · Phase 2
Glucagon-Like Peptide-1 Receptor Agonist in ADPKD
A Phase 2 study of Obesity and Autosomal Dominant Polycystic Kidney, sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 126
- Enrollment target
- 1
- Study location
NCT06582875: Recruiting Phase 2 study of Obesity and Autosomal Dominant Polycystic Kidney, sponsored by University of Colorado, Denver.
NCT06582875 is a Phase 2 study of Obesity and Autosomal Dominant Polycystic Kidney that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 126 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06582875, a Phase 2 study of Obesity and Autosomal Dominant Polycystic Kidney, is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 126 participants
- Enrollment target
- 1
- Study location
Study Summary
The proposed clinical trial aims to assess if a year of treatment with a glucagon-like peptide 1 receptor agonist, a medication approved for weight management that also improves the body's response to glucose and insulin, can slow kidney growth in adults with autosomal dominant polycystic kidney disease who are overweight or obese. The study will also evaluate changes in abdominal fat and kidney metabolism using cutting-edge images techniques. Blood and urine samples will provide further insight into biological changes that may be linked to the benefits of the intervention, while ensuring careful monitoring of safety and tolerability.
Primary Outcome
To assess kidney growth,height-adjusted total kidney volume will be measured by magnetic resonance imaging at baseline and 12 months to determine annual percent change.
Conditions Studied
Interventions
- DRUG Tirzepatide
- OTHER Placebo
Study Locations (1)
Colorado
- University of Colorado - Anschutz Medical Campus - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2025-03-06 |
| Est. Completion | 2029-06-30 |
| Phase | Phase 2 |
What NCT06582875 shows while recruiting
NCT06582875 is an interventional study that assigns participants to a tested intervention. The registered 126 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (85% lower).
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Tirzepatide is the first listed.
NCT06582875 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT06582875 about?
NCT06582875 is a clinical study titled "Glucagon-Like Peptide-1 Receptor Agonist in ADPKD". The proposed clinical trial aims to assess if a year of treatment with a glucagon-like peptide 1 receptor agonist, a medication approved for weight management that also improves the body's response to glucose and insulin, can slow kidney growth in adults with autosomal dominant polycystic kidney dis...
What is the current status of trial NCT06582875?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 126 participants. The study started on 2025-03-06. Estimated completion is 2029-06-30.
What conditions does trial NCT06582875 study?
This clinical trial studies the following conditions: Obesity, Autosomal Dominant Polycystic Kidney.
What interventions are being tested in trial NCT06582875?
The interventions under investigation include: Tirzepatide (DRUG), Placebo (OTHER).
Who is sponsoring clinical trial NCT06582875?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06582875 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06582875's enrollment target sits among peer trials
126 425th of 1053 higher than 629 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01873131 · 126 participants · NA
A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn
- NCT02621645 · 126 participants · Phase 4
TRAP Intervention STudy: Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence
- NCT03838107 · 126 participants
Markers of Trajectory in Pediatric CRPS
- NCT03906422 · 126 participants · NA
Comparison of Patient-reported Pain After Initial Archwire Placement
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI